Abstract
Pulmonary arterial hypertension (PAH) is a costly disease, both financially and personally. Survival rates have improved with targeted therapies, but could probably be improved more with aggressive management of medications to achieve low-risk status. Management of these patients requires complex, expensive regimens, which are likely best managed by a multidisciplinary team in a pulmonary hypertension center.
| Original language | English |
|---|---|
| Pages (from-to) | 73-78 |
| Number of pages | 6 |
| Journal | Journal of Managed Care Medicine |
| Volume | 22 |
| Issue number | 3 |
| State | Published - 2019 |
Fingerprint
Dive into the research topics of 'Clinical advances in the treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver